84,167 Shares in Hims & Hers Health, Inc. (NYSE:HIMS) Purchased by Legacy Capital Group California Inc.

Legacy Capital Group California Inc. bought a new stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS) in the second quarter, Holdings Channel reports. The fund bought 84,167 shares of the company’s stock, valued at approximately $1,699,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Vanguard Group Inc. grew its stake in Hims & Hers Health by 1.0% during the first quarter. Vanguard Group Inc. now owns 14,310,192 shares of the company’s stock valued at $221,379,000 after acquiring an additional 136,907 shares in the last quarter. Forerunner Ventures Management LLC purchased a new position in shares of Hims & Hers Health during the 4th quarter valued at $86,836,000. Dimensional Fund Advisors LP increased its holdings in shares of Hims & Hers Health by 9.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,147,927 shares of the company’s stock worth $19,117,000 after purchasing an additional 193,507 shares during the period. Farallon Capital Management LLC increased its holdings in shares of Hims & Hers Health by 3,890.5% in the first quarter. Farallon Capital Management LLC now owns 1,676,000 shares of the company’s stock worth $25,928,000 after purchasing an additional 1,634,000 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its position in shares of Hims & Hers Health by 1.7% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,294,759 shares of the company’s stock worth $11,523,000 after buying an additional 22,009 shares in the last quarter. 63.52% of the stock is currently owned by institutional investors.

Hims & Hers Health Trading Down 0.1 %

Shares of NYSE:HIMS traded down $0.02 on Tuesday, reaching $16.54. 6,506,404 shares of the company traded hands, compared to its average volume of 7,871,473. The stock has a market capitalization of $3.55 billion, a P/E ratio of -1,654.00 and a beta of 1.08. The business’s 50-day simple moving average is $20.37 and its 200 day simple moving average is $16.36. Hims & Hers Health, Inc. has a 52 week low of $5.65 and a 52 week high of $25.74.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings results on Monday, August 5th. The company reported $0.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.04 by $0.02. Hims & Hers Health had a negative return on equity of 0.70% and a negative net margin of 0.24%. The business had revenue of $315.65 million for the quarter, compared to analyst estimates of $302.43 million. During the same period last year, the company earned ($0.03) EPS. Hims & Hers Health’s revenue for the quarter was up 51.8% compared to the same quarter last year. Sell-side analysts expect that Hims & Hers Health, Inc. will post 0.2 EPS for the current fiscal year.

Insider Buying and Selling

In other Hims & Hers Health news, CEO Andrew Dudum sold 188,888 shares of the stock in a transaction on Monday, August 5th. The shares were sold at an average price of $16.47, for a total transaction of $3,110,985.36. Following the completion of the sale, the chief executive officer now owns 33,502 shares of the company’s stock, valued at approximately $551,777.94. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other Hims & Hers Health news, CEO Andrew Dudum sold 188,888 shares of the company’s stock in a transaction that occurred on Monday, August 5th. The stock was sold at an average price of $16.47, for a total transaction of $3,110,985.36. Following the completion of the transaction, the chief executive officer now owns 33,502 shares of the company’s stock, valued at approximately $551,777.94. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Soleil Boughton sold 2,502 shares of Hims & Hers Health stock in a transaction that occurred on Tuesday, May 28th. The stock was sold at an average price of $17.33, for a total value of $43,359.66. Following the completion of the sale, the insider now owns 156,855 shares in the company, valued at $2,718,297.15. The disclosure for this sale can be found here. Insiders have sold a total of 969,018 shares of company stock valued at $19,260,875 over the last three months. 17.71% of the stock is owned by company insiders.

Analysts Set New Price Targets

HIMS has been the topic of a number of research analyst reports. Piper Sandler restated a “neutral” rating and issued a $18.00 target price on shares of Hims & Hers Health in a research note on Tuesday, August 6th. Bank of America upped their price objective on shares of Hims & Hers Health from $22.00 to $26.00 and gave the stock a “buy” rating in a research report on Thursday, June 13th. Canaccord Genuity Group lifted their target price on shares of Hims & Hers Health from $20.00 to $24.00 and gave the company a “buy” rating in a research report on Wednesday, May 22nd. TD Cowen increased their price target on shares of Hims & Hers Health from $15.00 to $25.00 and gave the stock a “buy” rating in a report on Thursday, July 11th. Finally, Deutsche Bank Aktiengesellschaft lifted their price objective on shares of Hims & Hers Health from $16.00 to $23.00 and gave the stock a “hold” rating in a report on Wednesday, August 7th. Eight research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $20.00.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.